Expert commentary: The REWIND trial
John Wilding discusses how the results of the REWIND study add to our knowledge of the effects of the glucagon-like peptide-1 receptor agonist class in people with varying degrees of cardiovascular risk (3:37).
- News story | Dulaglutide cardioprotective in relatively low-risk REWIND population
- Expert commentary | A nurse educator’s view of the REWIND trial
- Expert commentary | A primary care view of the REWIND trial